Calixte Guehi

Publications (3)6.84 Total impact

• Article: Pharmacovigilance for antiretroviral drugs in Africa: lessons from a study in Abidjan, Cote d'Ivoire.

  Antoine Jaquet, Mariam Mama Djima, Patrick Coffie, Henri Die Kacou, Serge P Eholie, Eugene Messou, Albert Minga, Calixte Guehi, Jean Claude Yavo, Emmanuel Bissagnene, Francois Dabis, Didier K Ekouevi
  [show abstract] [hide abstract]
  ABSTRACT: Although antiretroviral treatment (ART)-related adverse drug reactions (ADR) are documented in industrialised countries, there is no pre-existing surveillance system dedicated to ADR monitoring in most African countries. We assessed knowledge towards pharmacovigilance among ART prescribers and available capacity of HIV clinics to conduct ADR monitoring in Abidjan, Côte d'Ivoire. A questionnaire was administered to ART prescribers to assess their knowledge towards the occurrence of ADRs. A retrospective ADR survey was also conducted based on a data query of treatment modification/interruptions in three HIV clinics. Clinical monitors went back to medical charts to review and validate the reasons of the treatment modification/interruptions. Of the 81 ART prescribers interviewed, 25 (31%) declared not grading ADRs and 12 (14.8%) declared notifying ADRs to the national regulatory authorities. Among 5252 adult ART-treated patients who attended the participating clinics in 2008, 599 treatment modifications were identified. Reasons for treatment modification/interruptions identified in the electronic database were documented in the medical charts in 554 cases (92.5%), ADR accounting for 273 cases (45.5%). Toxicity related to ART was graded in only 58 cases (21%) in the medical charts. This study describes challenges limiting the implementation of reliable pharmacovigilance activities in HIV clinics in Côte d'Ivoire. The lack of knowledge of ART prescribers concerning ADR grading does not support the spontaneous reporting of ADRs. Using treatment modification/interruptions for ADR monitoring appears feasible, but improvements are needed to respond to key questions related to drug toxicities in the context of ART scale-up in Africa.
  Pharmacoepidemiology and Drug Safety 07/2011; 20(12):1303-10. · 2.53 Impact Factor
• Article: Alcohol use and non-adherence to antiretroviral therapy in HIV-infected patients in West Africa.

  Antoine Jaquet, Didier K Ekouevi, Jules Bashi, Maiga Aboubakrine, Eugène Messou, Moussa Maiga, Hamar Alassane Traore, Marcel Djimon Zannou, Calixte Guehi, Franck Olivier Ba-Gomis, Albert Minga, Gérard Allou, Serge Paul Eholie, Emmanuel Bissagnene, Annie J Sasco, Francois Dabis
  [show abstract] [hide abstract]
  ABSTRACT: To investigate the association between alcohol use and adherence to highly active antiretroviral treatment (HAART) among human immunodeficiency virus (HIV)-infected patients in sub-Saharan Africa. Cross-sectional survey conducted in eight adult HIV treatment centres from Benin, Côte d'Ivoire and Mali. Participants and measurements During a 4-week period, health workers administered the Alcohol Use Disorders Identification Test to HAART-treated patients and assessed treatment adherence using the AIDS Clinical Trials Group follow-up questionnaire. A total of 2920 patients were enrolled with a median age of 38 years [interquartile range (IQR) 32-45 years] and a median duration on HAART of 3 years (IQR 1-4 years). Overall, 91.8% of patients were identified as adherent to HAART. Non-adherence was associated with current drinking [odds ratio (OR) 1.4; 95% confidence interval (CI) 1.1-2.0], hazardous drinking (OR 4.7; 95% CI 2.6-8.6) and was associated inversely with a history of counselling on adherence (OR 0.7; 95% CI 0.5-0.9). Alcohol consumption and hazardous drinking is associated with non-adherence to HAART among HIV-infected patients from West Africa. Adult HIV care programmes should integrate programmes to reduce hazardous and harmful drinking.
  Addiction 08/2010; 105(8):1416-21. · 4.31 Impact Factor
• Article: Tobacco use and its determinants in HIV-infected patients on antiretroviral therapy in West African countries.

  Antoine Jaquet, Didier Koumavi Ekouevi, Maiga Aboubakrine, Jules Bashi, Eugène Messou, Moussa Maiga, Hamar Alassane Traore, Marcel Zannou, Calixte Guehi, Franck-Olivier Ba-Gomis, Albert Minga, Gérard Allou, Serge Paul Eholie, Francois Dabis, Emmanuel Bissagnene, Annie-Jeanne Sasco
  [show abstract] [hide abstract]
  ABSTRACT: BACKGROUND: Tobacco smoking is common in human immunodeficiency virus (HIV) infected patients from industrialised countries. In West Africa, few data concerning tobacco consumption exist. METHODS: A cross-sectional survey of the International Epidemiological Database to Evaluate AIDS (IeDEA) network in West Africa was conducted. Health workers administered a questionnaire assessing tobacco and cannabis consumption among patients receiving antiretroviral treatment. Regular smokers were defined as current smokers who smoked >1 cigarette per day for >or=1 year. RESULTS: Overall, 2920 patients were enrolled in three countries. The prevalence of ever smokers and regular smokers were respectively 46.2% (95%CI 42.8-49.5) and 15.6% (95%CI 13.2-18.0) in men and 3.7% (95%CI 2.9-4.5) and 0.6% (95%CI 0.3-0.9) in women. Regular smoking was associated with being from Côte d'Ivoire or Mali compared to Benin (OR 4.6, 95%CI 2.9-7.3 and 7.7, 95%CI 4.4-13.6), severely impaired immunological status at highly active antiretroviral treatment initiation (OR 1.5, 95%CI 1.1-2.2) and history of tuberculosis (TB; OR 1.8, 95%CI 1.1-3.0). CONCLUSION: There are marked differences in smoking prevalence among these West African countries. This survey approach also provides proof of the association between cigarette smoking and TB in HIV-infected patients, a major public health issue in this part of the world.
  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.